Director Richard Chin of Cytek Biosciences, Inc. filed a Statement of Changes in Beneficial Ownership on November 20, 2026, reporting the vesting of restricted stock units on November 18, 2026.

Key Highlights

  • Reporting person: Richard Chin, identified as a Director of Cytek Biosciences, Inc. (NASDAQ:CTKB).
  • Transaction date: November 18, 2026, with transaction code M, reflecting the conversion of restricted stock units into common stock.
  • Units converted: 6,107 restricted stock units were acquired as common stock at a derivative price of $0, according to the filing.
  • Post-transaction common stock: Richard Chin directly held 34,606 shares of common stock following the reported transaction.
  • Remaining derivative holdings: 38,683 restricted stock units remained beneficially owned directly after the transaction, the filing disclosed.
  • Vesting schedule: The RSU award vests over 3 years across multiple dates, beginning with 2/36 of shares on August 18, 2025, according to the filing's explanation of responses.

Richard Chin's RSU Conversion and Beneficial Ownership at Cytek Biosciences

According to the filing, Richard Chin, a Director of Cytek Biosciences, Inc., reported a transaction dated November 18, 2026, in which 6,107 restricted stock units were converted into common stock via transaction code M. Cytek Biosciences is a life sciences instrumentation company listed on the NASDAQ exchange under the ticker CTKB. The filing identifies Chin's address as c/o Cytek Biosciences, Inc., 47215 Lakeview Boulevard, Fremont, California 94538.

The filing disclosed that each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Following the conversion, Chin's direct beneficial ownership of common stock stood at 34,606 shares. Separately, 38,683 restricted stock units remained outstanding under the derivative securities table, all held directly.

The RSU award vests over 3 years, the filing stated, with 2/36 of the total shares vesting on August 18, 2025; 3/36 vesting on November 18, 2025, and each November 18 thereafter; 3/36 vesting on March 10, 2026, and each March 10 thereafter; 3/36 vesting on May 18, 2026, and each May 18 thereafter; and 3/36 vesting on August 18, 2026, and each August 18 thereafter. The filing was signed by Wenbin Jiang as Attorney-in-Fact on November 20, 2026.

What Was Disclosed

The filing reported the vesting of 6,107 restricted stock units into common stock by Director Richard Chin of Cytek Biosciences, Inc. on November 18, 2026, leaving him with 34,606 shares of common stock and 38,683 restricted stock units directly held.